Cargando…

Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy

IL6 is one of the most elevated cytokines during chimeric antigen receptor (CAR) T cell cytokine release syndrome (CRS), and IL6R blockade by Tocilizumab has successfully relieved the most life-threatening aspects of CRS in patients. In addition, latest studies demonstrated the essential role of IL1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xue, Lei, Yi, Yan, Xu, Qianwen, Wang, Li, Yang, Xiaohui, Zhang, Yongjing, Hua, Xuefei, Chai, Xiaoshan, Yang, Junjie, Chen, Yaxin, Tao, Guangshi, Hu, Biliang, Wang, Xingbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437938/ https://www.ncbi.nlm.nih.gov/pubmed/34518515 http://dx.doi.org/10.1038/s41421-021-00299-6

Ejemplares similares

CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy
por: Yi, Yan, et al.
Publicado: (2021)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)

Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
por: Shen, Chunyi, et al.
Publicado: (2020)

Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
por: Li, Sujun, et al.
Publicado: (2019)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation
por: Xu, Qianwen, et al.
Publicado: (2022)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
por: Ormhøj, Maria, et al.
Publicado: (2022)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
por: Sun, Wei, et al.
Publicado: (2023)

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
por: Xie, Bailu, et al.
Publicado: (2022)

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
por: Heine, Renaud, et al.
Publicado: (2021)

Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
por: Zhou, Jianxia, et al.
Publicado: (2019)

Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells
por: Xu, Qianwen, et al.
Publicado: (2022)

Weathering the storm: COVID-19 infection in patients with hematological malignancies
por: Wang, Lin-qin, et al.
Publicado: (2020)

Tocilizumab, an IL6-receptor antibody, proved effective as adjuvant therapy for cytokine storm induced by severe infection in patients with hematologic malignancy
por: Wang, Bingjie, et al.
Publicado: (2023)

Development of Stable Chimeric IL-15 for Trans-Presentation by the Antigen Presenting Cells
por: Patidar, Manoj, et al.
Publicado: (2021)

Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review
por: Hanna, Kerollos S, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
por: Efficace, Fabio, et al.
Publicado: (2022)

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2021)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
por: Roex, Gils, et al.
Publicado: (2020)

The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead
por: Rohit Reddy, Sai, et al.
Publicado: (2021)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
por: Keshavarz, Ali, et al.
Publicado: (2022)

Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12
por: Chi, Xiaowei, et al.
Publicado: (2019)

The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study
por: Dong, Rujiao, et al.
Publicado: (2022)

Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
por: Chen, Nianci, et al.
Publicado: (2022)

Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer
por: Zhou, Fuxing, et al.
Publicado: (2018)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
por: Dixon, Brianne N., et al.
Publicado: (2020)

Chimeric antigen receptor engineered natural killer cells for cancer therapy
por: Zhang, Yalan, et al.
Publicado: (2023)

Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes
por: England, James T., et al.
Publicado: (2021)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q9dlstvlvui7on2ei2i6q6sldg